Faculty and Scientific Committee
Dr de Alarcon
University of Illinois College of Medicine Peoria
Graduate of Harvard College and the George Washington University School of Medicine. Completed medical residency at the Washington Hospital Center…
Graduate of Harvard College and the George Washington University School of Medicine. Completed medical residency at the Washington Hospital Center, pediatric residency at University of Vermont Medical Center and fellowship in pediatric hematology/oncology at SUNY Upstate Medical Center. Currently, William H. Albers, Professor and Head Department of Pediatrics at University of Illinois College of Medicine Peoria and adjunct member of St. Jude Children’s Research Hospital.
Dr Balwierz
Jagiellonian University Medical College in Krakow
The author of this biography has over 40 years of experience in the diagnosis and treatment of children with haematological and cancer diseases. The results of…
Main interest:
- Optimization of diagnostic and results of treatment for: acute leukemia, Hodgkin's Iymphoma, neuroblastoma and retinoblastomain children
- Late effects after treatment for childhood malignant neoplasms
The author of this biography has over 40 years of experience in the diagnosis and treatment of children with haematological and cancer diseases. The results of te study were vsed to make significant changes in the treatment of acute leukaemia programs,Hodgkin's Iymphoma,neuroblastoma and retinoblastoma as weil as to improve supportive care. Achievemen ts in academic and clinical werk are used in an international program to treat children with high-risk neuroblastoma (High Risk Neuroblastoma Study SIOPEN) and in First lntcrnationallnter-Group Study for classical HL in Children and adolescent (EuroNet PHL-C1and EuroNet-PHL-C2). The author of this biography from many years also has be-en focusing on the
problems of late complications in patients after treatment of cancer and improves the quality of life and
for over 30 years has participated in the clinicaltrials phase I-IV.
Prof. van den Berg
Universitair Medisch Centrum Groningen
Dr. Van den Berg (1963) is a professor at the Department of Pathology, working as a molecular clinical biologist in the pathology and as such involved in diagnostic…
Dr. Van den Berg (1963) is a professor at the Department of Pathology, working as a molecular clinical biologist in the pathology and as such involved in diagnostic testing of a broad spectrum of malignancies for molecular biomarkers relevant for diagnosis, prognosis or guiding treatment decisions. Her research is focused on the molecular pathogenesis of B cell lymphoma. She obtained her PhD on “The involvement of chromosome 3 deletions in renal cell carcinoma” and was appointed as professor in Molecular pathogenesis of malignant B-cell lymphoma in 2009. Her current research interests are focussed on the role of noncoding RNAs, including microRNAs, long noncoding and circular RNAS. In addition, she studies the value of tissue and circular biomarkers with a focus on molecular aberrations using NGS approaches.
Dr Bhakta
St. Jude Children´s Research Hospital
Nickhill Bhakta, MD, MPH is an assistant member in the Department of Global Pediatric Medicine at St. Jude Children’s Research Hospital. Dr. Bhakta earned…
Nickhill Bhakta, MD, MPH is an assistant member in the Department of Global Pediatric Medicine at St. Jude Children’s Research Hospital. Dr. Bhakta earned his bachelor’s degree with honors in history from Brown University, medical degree from the University of Cincinnati College of Medicine and master’s in public health from the Harvard School of Public Health before coming to St. Jude in 2013 as a Clinical Fellow in Pediatric Hematology/Oncology. In 2016, he joined the faculty of St. Jude Children’s Research Hospital to lead two programs. As Director of the Sub-Saharan Africa Region, Dr. Bhakta coordinates St. Jude Global capacity building efforts in the region. Additionally, as Director of the Disease Burden and Simulation Unit, Dr. Bhakta has developed an epidemiology research program focusing on global disease burden, cancer survivorship, and cost-effectiveness. In addition to his academic and regional units, Dr. Bhakta also co-leads the ARIA Guide program, a multistakeholder global initiative to provide locally adapted guidance to partners treating children regardless of their local resource availability.
Dr Binkley
Stanford University
Dr. Mike Binkley is a radiation oncologist at Stanford University with clinical and research interests in developing personalized treatments for patients with lymphoma…
Dr. Mike Binkley is a radiation oncologist at Stanford University with clinical and research interests in developing personalized treatments for patients with lymphoma incorporating imaging and genomics. He most recently co-founded a new pediatric and adult global initiative with Dr. Jamie Flerlage called GLOW (Global nLPHL One Working group).
Dr Bollard
Children's National Hospital
Dr. Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is board certified both in pediatrics and hematology. She worked in…
Dr. Bollard received her medical degree at the University of Otago in Dunedin, New Zealand. She is board certified both in pediatrics and hematology. She worked in New Zealand and London, England, before moving to Houston, Texas, in 2000 where she was a Professor of Pediatrics, Medicine, and Immunology at Baylor College of Medicine (BCM) and the Director of the Texas Children’s Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she was recruited to Washington, DC, to join Children’s National Hospital and The George Washington University School of Medicine and Health Sciences. She is currently the Bosworth Chair for Cancer Biology, the Director of the Center for Cancer and Immunology Research, and the Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI) at Children’s National Hospital. She is a Professor of Pediatrics and of Microbiology, Immunology, and Tropical Medicine at The George Washington University and the Associate Center Director for Translational Research and Innovation at the GW Cancer Center.
Dr. Bollard is a member of the American Society for Clinical Investigation (ASCI), is a past president of the International Society for Cellular Therapy (ISCT) and is the current President of the Foundation for the Accreditation of Cellular Therapy (FACT). She was a member of the Cellular, Tissues, and Gene Therapies Advisory Committee of the Food and Drug Administration (FDA) from 2015 to 2019 and in 2019 she became a member of the Frederick National Laboratory Advisory Committee (FNLAC) for the NIH and an ad hoc member of the Pediatric Oncologic Drugs Advisory Committee (ODAC) for the FDA. She has been an associate editor for the journal Blood since 2014 and recently was appointed Editor in Chief of Blood Advances. She has >200 peer reviewed publications and has been independently NIH funded for over a decade. Her bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation and on the development of novel cell therapies for cancer and virus-associated diseases.
Dr Bräuninger
Justus-Liebig-Universität Gießen
To follow
Prof. Burkhardt
University Hospital Münster
Birgit Burkhardt, MD, PhD, is Professor for Pediatrics at the University Children’s Hospital in Münster. She is head of the pediatric bone marrow transplant program and…
Birgit Burkhardt, MD, PhD, is Professor for Pediatrics at the University Children’s Hospital in Münster. She is head of the pediatric bone marrow transplant program and the pediatric lymphoma program in Münster, Germany. The research focus of her group is translational and clinical research on the molecular mechanisms of pathogenesis in Non-Hodgkin lymphoma and the transfer of the growing understanding into optimized patient care. She is chair of the NHL-BFM study group (since 2011 with Prof. Woessmann, UKE); 2.nd vice chair of the German Society of Pediatric Hematology and Oncology (GPOH) (since 2019); Co-Chair of the NHL-BFM Registry 2012 with population based recruitment of NHL in Germany, International Principal Investigator of the academic investigator initiated clinical trials B-NHL 2013 (NCT03206671) and LBL 2018 (NCT04043494).
Dr Cairo
New York Medical College, Westchester Medical Center, Maria Fareri Children´s Hospital
Dr. Cairo is currently the Associate Chairman and Professor (with tenure) in the Department of Pediatrics at New York Medical College (NYMC). His additional current…
Dr. Cairo is currently the Associate Chairman and Professor (with tenure) in the Department of Pediatrics at New York Medical College (NYMC). His additional current leadership positions include being the Chief of the Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Director of the Childhood and Adolescent Cancer and Blood Disease Center, Medical and Scientific Director of the Cellular and Tissue Engineering Laboratory at Westchester Medical Center (WMC), Medical Director of the WMC Hematotherapy Program and Director of the WMC Cancer Center. Dr. Cairo’s additional academic appointments include being a Professor of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology and Anatomy and Public Health at NYMC.
Briefly, Dr. Cairo’s past education includes his undergraduate studies at the University of Wisconsin, Madison, WI, graduating in 1972 with a BA and election to Phi Beta Kappa. Dr. Cairo received my medical school training at the University of California, San Francisco (USCF) graduating in 1976 and election to Alpha Omega Alpha (AOA). Dr. Cairo trained as a Pediatric Resident at UCLA Harbor General from 1976-1978 under the mentorship of Joseph St. Geme, MD and then a Chief Residency in Pediatrics from 1978-1979 at UCSF under the mentorship of Melvin Grumbach, MD. Dr. Cairo completed a Pediatric Hematology-Oncology Fellowship as an American Cancer Society Fellow at Indiana University from 1979-1981 under the mentorship of Robert Baehner, MD.
Dr. Cairo joined the faculty of Children’s Hospital of Orange County (CHOC) in 1982 and established the BMT/Stem Cell Transplant program there in 1985 as Director of Blood and Marrow Transplantation. Also, at CHOC Dr. Cairo was the Principal Investigator (PI) for Children’s Cancer Group and PI of the Cord Blood Collection Center and Cord Blood Transplant Center under an NHLBI award. In 1997, Dr. Cairo was recruited to Georgetown University where he became a Professor of Pediatrics, Medicine and Pathology and Chief of the Division of Stem Cell Transplantation, Cellular and Gene Therapy and Director of the Adult Bone Marrow Transplantation program at the Lombardi Cancer Center and Medical Director of the NHLBI Cord Blood Collection Center. In 2000, Dr. Cairo was recruited to Columbia University and was a Professor of Pediatrics, Medicine and Pathology and Director of the Division of Blood and Marrow Transplantation, member of the executive committee of the Department of Pediatrics, Medical Director of the National Marrow Donor Unrelated Transplant program, Chief of the Division of Pediatric Blood and Marrow Transplantation and member of the executive steering committee of the Morgan Stanley Children’s Hospital of NewYork-Presbyterian Hospital. In 2011 Dr. Cairo was recruited to NYMC and WMC.
Dr. Cairo has over 450 peer reviewed publications, over 1300 national and international abstract presentations, over 50 book chapters and edited 2 textbooks. Dr. Cairo is an international leader in the biology and treatment of childhood and adolescent lymphomas and leukemias, stem cell transplantation, developmental therapeutics, experimental hematopoiesis and immunology and stem cell biology and regenerative therapy. Dr. Cairo was a pioneer in the use of cord blood stem cells for treating pediatric malignant and non-malignant disease, the use of cord blood stem cells for potential regenerative therapy and stem cell transplantation for sickle cell disease. Dr. Cairo is a member of a number of national and international societies related to both pediatrics and my specialty, Hematology/Oncology/Stem Cell Transplantation, including, elected to the Society of Pediatric Research (SPR) and the American Pediatrics Society (APS) and member of AAP, ESPR and hematology and oncology and stem cell transplantation societies such as ASH, ASCO, ASBMT, AAI, ISEH, AACR, ASPHO, SIOP, PBMTC and COG.
Dr. Cairo has been a leader in basic, translational and clinical research in childhood, adolescent and young adults with cancer and blood diseases. Dr. Cairo has been the chair of several NCI/CCG/COG national and international clinical trials. Dr. Cairo is the co-editor of the textbook Hematological Malignancies in Children, Adolescents and Young Adults.
Prof. Castellino
Emory Universtiy/Children's Healthcare Atlanta
Dr. Castellino is a Professor of Pediatrics in the Division of Hematology and Oncology at Emory University and the Director of the Leukemia and Lymphoma program…
Dr. Castellino is a Professor of Pediatrics in the Division of Hematology and Oncology at Emory University and the Director of the Leukemia and Lymphoma program Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta, in Atlanta GA. She has been the study chair for AHOD1331, the recently completed Children’s Oncology Group trial for High Risk Hodgkin Lymphoma and for S1826, a NCTN collaborative study for advanced stage HL in patients > 12 years of age. Her interests are in outcomes supportive care and cancer control beyond disease free survival in children, adolescents and young adults with hematologic malignancies.
Dr Cole
Rutgers Cancer Insitute
Peter Cole, MD is the Embrace Kids Foundation Endowed Chair and Professor of Pediatrics at the Rutgers Cancer Institute of New Jersey, where he is also the Chief…
Peter Cole, MD is the Embrace Kids Foundation Endowed Chair and Professor of Pediatrics at the Rutgers Cancer Institute of New Jersey, where he is also the Chief of the Division of Pediatric Hematology Oncology. As Vice Chair of the Children’s Oncology Group’s Hodgkin Disease Committee, he has been responsible for overseeing clinical trials testing novel strategies for children, adolescents, and young adults with relapsed or refractory Hodgkin lymphoma.
Prof. Constine
University of Rochester
The Philip Rubin Professor of Radiation Oncology and Pediatrics
Director, The Judy DiMarzo Cancer Survivorship Program…
The Philip Rubin Professor of Radiation Oncology and Pediatrics
Director, The Judy DiMarzo Cancer Survivorship Program
Vice Chair, Department of Radiation Oncology
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Louis S. Constine, MD, FASTRO, FACR is Professor of Radiation Oncology and Pediatrics and Vice Chair of the Department of Radiation Oncology. He was awarded fellowships in his professional society, The American Society of Radiation Oncology, in 2008, and in The American College of Radiology in 2018. After graduating from Stanford University, and The Johns Hopkins University School of Medicine, he trained in pediatrics, pediatric oncology and radiation oncology, and has board certification in these areas. His clinical and scientific expertise is in lymphomas, sarcomas, all pediatric malignancies, and the broad area of Survivorship that includes the acute and chronic effects of chemotherapy and radiation therapy on normal tissues.
He is the Director of the University of Rochester Medical Center (Judy DiMarzo) Survivorship Program, and the Radiation Chair of the Lymphoma Committee in the Southwest Oncology Group. He is on the core committees for the Children’s Oncology Group Survivorship Guidelines, the International Survivorship Harmonization Guidelines, previously was on the American Society of Clinical Oncology Survivorship Advisory Group, and he leads the Pediatric Quantitative Analysis of Normal Tissue Effects in the Clinic ASTRO/AAPM initiative. He serves on the Children’s Oncology Group Late Effects Steering Committee, is senior advisor for the COG Hodgkin Lymphoma Committee, and is on the executive committee of the Radiation Oncology Committee (leading an effort to compile normal tissue dose constraints for protocols). He has been an investigator on several grants including an ROI evaluating long-term cardiac toxicities in Hodgkin lymphoma survivors. He is a member of the steering committee for the NCI-supported Childhood Cancer Survivorship Study and am actively involved in select projects. He was a member of a four-person United Nations task force collating the adverse effects of radiation on children; he discussed their 240 page document at the UN international headquarters (Vienna) in 5/12 and again in 5/13 and it was internationally distributed. Other international efforts included his core membership on an International Atomic Energy Agency initiative to develop pediatric radiation oncology in low-income countries that met in Vienna in 6/13. Additional activities included membership on task forces for the American Heart Association on cardiotoxicity, and the National Council on Radiation Protection Scientific Committee on “Second Primary Cancers and Cardiovascular Disease after Radiation Therapy.”
He is recipient of an NIH merit award in 2010, the Jacob Gitelman Award from Cancer Action, the “Make a Difference” Award from Melissa’s Legacy, and the Teddy award from Camp Good Days and Special Times. He is included in the America’s Top Doctors for Cancer. He is a member of numerous societies including The American Society of Radiation Oncology, the Radiation Research Society, the American Society of Clinical Oncology, and the American Society of Hematology. He has authored (co-authored) edited more than 50 book chapters (including the 6th edition of Pediatric Radiation Oncology- British Medical Book Award), edited eight books and ~260 original and invited reports.
His professional life is guided by his words: For the survivor of cancer, the world is full and each day is a celebration -- for the physician, each patient is an inspiration --for the person fighting cancer, each day is precious and must be faced with courage.
Prof. Dalla-Favera
Hospital Universitario Austral
Riccardo Dalla-Favera was born in Legnano, Italy, in 1951 and grew up in Milan. He obtained his Medical Doctor degree from University of Milan. He moved to…
Riccardo Dalla-Favera was born in Legnano, Italy, in 1951 and grew up in Milan. He obtained his Medical Doctor degree from University of Milan. He moved to the U.S. in 1978 to join as a Fogarty Fellow the Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health. In 1983 he joined the faculty of New York University, and in 1989 moved to Columbia University, where he is a Professor of Pathology & Cell Biology. In 1999 Dr. Dalla-Favera founded The Institute for Cancer Genetics at Columbia University, and to this day remains the Director. From 2005-2011, he also served as Director of the Herbert Irving Comprehensive Cancer Center at Columbia University
Dr. Dalla-Favera’s area of research is cancer genetics. His research team has contributed significantly to the understanding of the pathogenesis of cell malignancies, including B Cell Lymphoma, and Chronic Lymphocytic Leukemia. His work is quoted in major textbooks of medicine and oncology as it directly impacts the diagnostics and therapeutic targeting of these diseases.
Dr. Dalla-Favera’s work is widely recognized by numerous National and International prizes and awards, including the 2006 William Dameshek Prize from the American Society of Hematology (ASH), the 2017 American Association for Cancer Research GHA Clowes Memorial Award, and the 2017 Léopold Griffuel Award in Basic Research from the Association pur la Reserche sur le Cancer (ARC), France. He is an elected member of the U.S. National Academy of Medicine and the U.S. National Academy of Sciences.
Dr Daw
University College Hospital London
To follow
Prof. Dieckmann
Medizinische Universität Wien
To follow
Dr Diepstra
Universitair Medisch Centrum Groningen
Arjan Diepstra, MD,PhD is a consulting hematopathologist and principal investigator at the University Medical Center Groningen in the Netherlands…
Arjan Diepstra, MD,PhD is a consulting hematopathologist and principal investigator at the University Medical Center Groningen in the Netherlands.
He received his medical degree in 2000 and combined pathology training with a PhD study. In his PhD thesis "Classical Hodgkin lymphoma: population based studies on HLA and EBV" he discovered that the HLA system is intricately involved in Hodgkin lymphoma susceptibility, pathogenesis and prognosis. In 2007 he became a staff member at the department of pathology of the UMC Groningen and received a Dutch Cancer Society fellowship to work in the lab of prof. Alan Rickinson at the University of Birmingham in the United Kingdom on the project “Functional studies on Epstein Barr virus specific immune responses against tumor cells in classical Hodgkin lymphoma”. He is an active member of the Interlymph consortium, the EORTC lymphoma group and the Hemato oncology foundation for adults in the Netherlands (HOVON) and is responsible for several translational research projects in Hodgkin lymphoma clinical trials. His research interests are focused on genetic susceptibility, pathogenesis and translational applications in Hodgkin lymphoma, in particular pertaining to the cross-talk between Hodgkin-Reed Sternberg cells and T cells.
Dr Ehrhardt
St. Jude Children´s Research Hospital
Dr. Matthew Ehrhardt is an Assistant Member in the Division of Cancer Survivorship at St. Jude Children’s Research Hospital. Dr. Ehrhardt received his…
Dr. Matthew Ehrhardt is an Assistant Member in the Division of Cancer Survivorship at St. Jude Children’s Research Hospital. Dr. Ehrhardt received his medical degree from the University of Illinois College of Medicine at Peoria and completed training in pediatrics, internal medicine, and pediatric hematology/oncology/blood and marrow transplantation at the Medical College of Wisconsin. He completed an additional year of training in childhood cancer survivorship at St. Jude Children’s Research Hospital where he currently specializes in the care of children newly diagnosed with Hodgkin and non-Hodgkin lymphoma and long-term survivors of childhood cancer. He is currently Co-Chair of the Cardiac Task Force and Member of the Expert Panel for the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, as well as a member of the COG Non-Hodgkin Lymphoma Committee. He is Co-Chair of the Cardiomyopathy and Renal Late Effects Working Groups of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) and a member of the American Society of Clinical Oncology (ASCO) Survivorship Guideline Advisory Group. Dr. Ehrhardt’s clinical research is focused on the long-term effects of childhood cancer therapy and surveillance guideline development, dissemination, and utilization.
Dr Flerlage
St. Jude Children´s Research Hospital
Jamie E. Flerlage, MD, MS, is an Assistant Member in the Department of Oncology AQ3 at St. Jude Children’s Research Hospital, leads the…
Jamie E. Flerlage, MD, MS, is an Assistant Member in the Department of Oncology AQ3 at St. Jude Children’s Research Hospital, leads the St. Jude-Stanford-Dana-Farber Pediatric Hodgkin Consortium, and serves as PI of the current frontline trial. She obtained her undergraduate and medical degrees at Union College and Albany Medical College in Albany, New York, and completed pediatric residency at Johns Hopkins Children’s Center. Dr. Flerlage performed pediatric hematology/ oncology training at St. Jude Children’s Research Hospital. In an effort to improve the care for pediatric Hodgkin lymphoma around the world, she leads an international working group, SEARCH for CAYAHL, to harmonize staging and response criteria across all consortia. She serves as a member of the Children’s Oncology Group Hodgkin Lymphoma steering committee, is a co-leader of NODAL, the Hodgkin subgroup of the Pediatric Cancer Data Commons, and most recently co-founded a new pediatric and adult global initiative with Michael Binkley from Stanford called GLOW (Global nLPHL One Working group)
Prof. Gattenlöhner
Justus-Liebig University
To follow
Dr Geel
University of the Witwatersrand
Dr Jennifer Geel is passionate about improving the survival and quality of life of children with cancer. She trained at UCT Medical School, completed her internship…
Dr Jennifer Geel is passionate about improving the survival and quality of life of children with cancer. She trained at UCT Medical School, completed her internship at Chris Hani Baragwanath Academic Hospital and community service at Umtata General Hospital in the late nineties. She then spent two years in clinical research settings in Cape Town and London before specialising in paediatrics. She subsequently subspecialised in paediatric oncology and has a strong interest in stem cell transplantation.
Dr Geel serves on the committee of the South African Children’s Cancer Study Group (SACCSG), and headed the SACCSG team in the creation of a national cancer prevention and control plan, in conjunction with the National Department of Heath and the Cancer Alliance. She is the Principal Investigator of a national Hodgkin lymphoma trial.
Dr Geel is a former Co-chair of the Education and Training working group of International Paediatric Oncology Society (SIOP) Paediatric Oncology in Developing Countries (PODC) committee and a core member of the SIOP Global Mapping Programme. She is an ardent advocate of access to quality health care, childhood cancer awareness, mentoring, development of postgraduates, harmonisation of protocols, the use of social media to promote health and mindful practice of oncology.
Dr Giulino Roth
Weill Cornell Medicine
Dr. Lisa Roth is an Associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Weill Cornell Medical College. She serves as the Director…
Dr. Lisa Roth is an Associate Professor of Pediatrics in the Division of Pediatric Hematology/Oncology at Weill Cornell Medical College. She serves as the Director of the Pediatric Oncology Program and the Adolescent and Young Adult Lymphoma Program at Weill Cornell Medicine/New York Presbyterian Hospital.
Dr. Roth completed her undergraduate work at Duke University. She received her medical degree from New York University School of Medicine. Dr. Roth conducted her residency in Pediatrics at NewYork-Presbyterian/Weill Cornell and her fellowship in Pediatric Hematology/Oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian where she served as chief fellow.
Dr. Roth’s laboratory research focuses on identify novel therapeutic targets for pediatric lymphomas including Hodgkin lymphoma and aggressive B-cell non-Hodgkin lymphoma. Her laboratory work is closely tied to her clinical research where she is leading several national clinical trials focused on advancing therapy for children, adolescents, and young adults with Hodgkin and non-Hodgkin lymphoma. Dr. Roth has been recognized for her work with a K08 award from the NCI (2017), an ASCI Young Investigator Award (2021), and an ASH Scholar Award (2021).
Dr Hasenclever
Universitätsklinikum Leipzig
Dr. Dirk Hasenclever is Senior Biometrician at the Institute for Medical Informatics, Statistics & Epidemiology (IMISE), University Leipzig, Germany. Specialising in…
Dr. Dirk Hasenclever is Senior Biometrician at the Institute for Medical Informatics, Statistics & Epidemiology (IMISE), University Leipzig, Germany. Specialising in study design and methodology, he cooperates closely with the Clinical Trial Centre (ZKS) Leipzig, which currently supports about 90 ongoing clinical trials.
Dirk Hasenclever studied Mathematics and Physics in Bonn, and Philosophy and General Linguistics in Cologne, Germany.
From 1985 to 1995 he was involved as biometrician in several trials of the German Hodgkin’s Lymphoma Study Group.
In 1995 he got a PhD (Dr. rerum medicinalium) from the Medical Faculty at the University of Cologne with a mathematical model of tumour growth and chemotherapy in Hodgkin Lymphoma, which was instrumental in designing and predicting outcome with the BEACOPP regimen in advanced stage adult Hodgkin Lymphoma.
In 1998 he developed and published the International Prognostic Score for advanced Hodgkin Lymphoma.
Since the foundation of EuroNet-PHL in 2005, Dirk Hasenclever is the responsible Biometrician of the European Network for Paediatric Hodgkin Lymphoma and member of its Clinical Board.
In 2014, he helped developing the qPET method for early response assessment with FDG-PET.
In 2017, Dirk Hasenclever received the ISCAYAHL Günther Schellong Award for childhood and adolescent Hodgkin lymphoma.
Dr Hennewig
Universitätsklinikum Gießen
To follow
Prof. Hodgson
Princess Margaret Cancer Centre
Dr. Hodgson is a Professor in the Department of Radiation Oncology, and the Institute for Health Policy, Management and Evaluation, University of Toronto. He is the…
Dr. Hodgson is a Professor in the Department of Radiation Oncology, and the Institute for Health Policy, Management and Evaluation, University of Toronto. He is the Medical Director of the Pediatric Oncology Group of Ontario (POGO), and holds the POGO Chair in Childhood Cancer Control at the University of Toronto. In addition to practicing radiation oncology in the lymphoma and pediatric site groups at the Princess Margaret Cancer Centre, he is a member of the Hodgkin Lymphoma Steering Committee of the Children’s Oncology Group.
Dr Hoppe
Mayo Clinic Florida
Bradford S. Hoppe MD, MPH is a Professor of Radiation Oncology and Medical Director of Particle Therapy at Mayo Clinic Florida. His research focuses on the…
Bradford S. Hoppe MD, MPH is a Professor of Radiation Oncology and Medical Director of Particle Therapy at Mayo Clinic Florida. His research focuses on the introduction of new radiotherapy (RT) modalities (including intensity-modulated radiation therapy (IMRT), proton therapy, and carbon ion therapy). He is a member of the NCCN pediatric Hodgkin lymphoma committee and radiation oncology lead of the Children’s Oncology Group (COG) pediatric Hodgkin lymphoma committee. He is an investigator for the COG AHOD 1331 clinical trial and chaired the radiation guidelines for AHOD 1721, AHOD 1822, as well as the upcoming AHOD2131. He also chairs the Particle Therapy Cooperative Group (PTCOG) lymphoma committee and, in addition, am a member of the International Lymphoma Radiation Oncology Group (ILROG) steering committee, co-leading the effort to develop evidence-based guidelines for using proton therapy in lymphoma for both groups.
Dr Hudson
St. Jude Children´s Research Hospital
Melissa M. Hudson, MD, is currently a Member and Director of the Cancer Survivorship Division in the…
Melissa M. Hudson, MD, is currently a Member and Director of the Cancer Survivorship Division in the Department of Oncology and holds the Charles E. Williams Endowed Chair of Oncology-Cancer Survivorship. She directs the St. Jude After Completion of Therapy (ACT) Program, which now monitors over 6000 long-term childhood cancer survivors treated on St. Jude trials. Dr. Hudson disseminated the St. Jude model of risk-based survivor care in her role as Co-Chair of the Children’s Oncology Group (COG) Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer and Co-Chair of the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG). She is also the Chair of the Education Committee of the Childhood Cancer Survivor Study (CCSS) and a member of the CCSS Executive Committee. She works collaboratively with multidisciplinary investigators at St. Jude and within COG, IGHG and the CCSS in research initiatives evaluating biomedical and psychosocial outcomes among childhood cancer survivors and translating data from health outcomes research into evidence-informed clinical practice guidelines and interventions to improve the quality and duration of survival after childhood cancer. She has published widely on her research initiatives related to late treatment sequelae after childhood cancer and health surveillance of childhood cancer survivors.
Dr Kaste
St. Jude Children´s Research Hospital
Dr. Sue Kaste is a pediatric body radiologist at St. Jude Children’s Research Hospital, Memphis, TN, with more than 30 years’ experience in pediatric oncologic…
Dr. Sue Kaste is a pediatric body radiologist at St. Jude Children’s Research Hospital, Memphis, TN, with more than 30 years’ experience in pediatric oncologic imaging. She participates in a wide variety of clinical research protocols but Dr. Kaste’s primary research focus is skeletal toxicities in survivors of childhood cancer.
Dr Kelly
Roswell Park Comprehensive Cancer Center
Dr. Kara Kelly is the Waldemar J. Kaminski Endowed Chair of Pediatrics and Professor of Oncology at Roswell Park Comprehensive Cancer Center and Division Chief of…
Dr. Kara Kelly is the Waldemar J. Kaminski Endowed Chair of Pediatrics and Professor of Oncology at Roswell Park Comprehensive Cancer Center and Division Chief of Pediatric Hematology/Oncology at Oishei Children’s Hospital and the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo where she also is a Professor of Pediatrics. A pediatric oncologist with expertise in the care of children and adolescents with leukemia and lymphoma, Dr. Kelly has been chair of the Hodgkin lymphoma committee for the Children’s Oncology Group since 2011. In her current role, she oversees the development and conduct of a large portfolio of clinical trials and correlative studies aimed at improving the care of children and adolescents with Hodgkin lymphoma through the integration of novel therapeutic strategies.
Prof. Kluge
Universitätsklinikum Leipzig
Regine Kluge is specialized in nuclear medicine and the deputy director of the Department of Nuclear Medicine at the University of Leipzig. She is the responsible nuclear…
Regine Kluge is specialized in nuclear medicine and the deputy director of the Department of Nuclear Medicine at the University of Leipzig. She is the responsible nuclear physician in the EuroNet-PHL trials and was involved in the development of the FDG-PET/CT response criteria in paediatric Hodgkin lymphoma. She and her team performed the central reference reading of the PET/CT for staging and response assessment in EuroNet-PHL-C1, -C2 . –LP and -R1.
Prof. Körholz
Justus-Liebig-University
Education and training
01.10.1978-31.12.1984 University of Düsseldorf, Medical School…
Education and training
01.10.1978-31.12.1984 University of Düsseldorf, Medical School
01.11.1987-18.02.1990 Grant of the German Research Association. (Albert Ernst College of Medicine NY, NY, USA)
Work Experience
Residency
01.01.1985-31.12.1993
University of Düsseldorf, Moorenstraße 5, 40225 Düsseldorf
AUending Physician
01.01.1994- 01.05.1999 University of Düsseldorf, Moorenstraße 5, 40225 Düsseldorf
Academic Positions
Prof. of Ped. Hematology/Oncology 01.05.1999-28.02.2006 University of Leipzig, Liebigstraße 22, 04107 Leipzig
Director of the clinic, Professor of Paediatrics 01.03.2006- 31.7.2015 Martin-Luther-University, Children's Hospital, Ernst-Grube-Str. 40, 06097 Halle
Head Division of Pediatric Hematology and Oncology Prof of Paediatric Haematology and Oncology Since 1.8.2015 Justus Liebig University Feulgenstr. 10 - 12 35392 Gießen
1.10.2010-30.09.2014 Martin-Luther-University, Halle-Wittenberg Dean of Student Affairs
1.11.2014-31.7.2015 Martin-Luther-University, Halle-Wittenberg Vice President
Since 1.10.2018 Justus Liebig University Gießen Dean of Student Affairs
Main activities and responsibilities
Hodgkin Lymphoma: Clinical and experimental research
Coordination Chairperson
EuroNet-PHL-C 1, LP 1 and C2 trails
Experience as investigator in more than 10 clinical trials
Dr Krasin
St. Jude Children´s Research Hospital
I serve as a Full Faculty Member in the Department of Radiation Oncology at St. Jude Children’s Research Hospital. My clinical and academic activities are focused…
I serve as a Full Faculty Member in the Department of Radiation Oncology at St. Jude Children’s Research Hospital. My clinical and academic activities are focused on pediatric solid tumors and Hodgkin lymphoma, their radiation late effects, and how modalities like proton beam radiation may mitigate these effects. Therapy specific accomplishments include completion of sequential investigator initiated trials for pediatric rhabdomyosarcoma, implementation and study of conformal type treatment guidelines (including proton beam) for Hodgkin lymphoma and most recently developing an investigator initiated trial for Wilms’ tumor incorporating conformal targeting guidelines and proton beam radiation. My research focus includes improving the radiation target definitions for solid tumors and Hodgkin lymphoma while maintaining local disease control, as well as defining the relationships between radiation dose, volume treated and late side effects.
Prof. Küppers
Universitätsklinikum Duisburg-Essen
Ralf Küppers studied biology at the University of Cologne (Germany). He performed his Ph.D. studies in the group of Klaus Rajewsky in Cologne, obtaining his Ph.D. in…
Ralf Küppers studied biology at the University of Cologne (Germany). He performed his Ph.D. studies in the group of Klaus Rajewsky in Cologne, obtaining his Ph.D. in 1995. In 1999 he became lecturer (Privatdozent). In 2000/2001, he stayed for a sabbatical at the Columbia University in New York with Riccardo Dalla-Favera. After this, he returned to Cologne. Since 2004 he is professor of Molecular Genetics at the Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
The research of Ralf Küppers is focussed on the pathogenesis of human B-cell lymphomas and the differentiation and function of normal mature B cells in humans.
Dr Landman-Parker
Hôpital À.Trousseau
Professor of pediatrics Sorbonne University Paris France / pediatric hematology oncology department APHP Hôpital A Trousseau Paris France…
Date of birth 14.02.1960
4 children
Professor of pediatrics Sorbonne University Paris France / pediatric hematology oncology department APHP Hôpital A Trousseau Paris France
Clinical board member of the Euronet Hodgkin group
SFCE Lymphoma committee member
ITCC educational committee
Sylvain Latour
Inserm 1163-IMAGINE Institute
Sylvain LATOUR is a senior scientist of the Centre National de la Recherche Scientifique (CNRS) in France. He is the head of the laboratory “Activation lymphocytaire…
Sylvain LATOUR is a senior scientist of the Centre National de la Recherche Scientifique (CNRS) in France. He is the head of the laboratory “Activation lymphocytaire et susceptibilité au virus d’Epstein Barr” at Imagine Institute in Paris. He obtained his PhD in Immunology in 1995. He is an internationally recognized expert in the field of primary immunodeficiencies and T-cell activation. His team is particularly involved the identification and the characterization of primary immunodeficiencies associated with high susceptibility to Epstein Barr virus infection. He has recently developed projects to identify and characterize the molecular and genetic bases of childhood EBV+ lymphomas.
Dr Leblanc
Hôpital Robert-Debré - APHP
I spent 20 years in Hôpital Saint-Louis and I currently work in Hôpital Robert-Debré where I am in charge of the patients with lymphoma in collaboration with…
Thierry LEBLANC, M.D.
Pediatrician and hematologist. Hôpital Robert-Debré. Assistance Publique – Hôpitaux de Paris. 75019 Paris and EA 3518. Institut de Recherche Saint-Louis. Université Paris-Diderot. Paris.
I spent 20 years in Hôpital Saint-Louis and I currently work in Hôpital Robert-Debré where I am in charge of the patients with lymphoma in collaboration with the Hôpital Saint-Louis team lymphoma and AYA teams.
Current president of the lymphoma committee of the French Society for childhood cancer (SFCE) and member of the EuroNet Clinical Board.
Prof. Lederman
GRAACC
To follow
Prof. Lim
University of Pennsylvania
MEGAN S. LIM, MD, PhD is the Director of the Division of Hematopathology, Hospital of the University of Pennsylvania, and Professor within the Department…
MEGAN S. LIM, MD, PhD is the Director of the Division of Hematopathology, Hospital of the University of Pennsylvania, and Professor within the Department of Pathology and Laboratory Medicine, Director of the Hematopathology Fellowship Program, and the Director of the Lymphoma Biology Program at the Abramson Cancer Center.
Dr. Lim received an MD from the University of Calgary and a PhD in Molecular Oncology from the University of Calgary and National Cancer Institute Lab of Pathology jointly. Dr. Lim obtained her Hematopathology fellowship training at the National Cancer Institute after which she assumed a faculty position at the University of Toronto (1998-2000), the University of Utah (2000-2006). the University of Michigan (2006-2015) before moving to the University of Pennsylvania in 2015. Dr. Lim is certified by the American Board of Pathology in Anatomic Pathology, with subspecialty certification in Hematopathology and Molecular Genetic Pathology. She has held numerous leadership positions and served on training and education committees for the Association of Molecular Pathology and the United States Academy of Pathology. She has served as a member of the Board of Directors for the United States Academy of Pathology. She contributes to the scientific missions of the Children’s Oncology Group (Vice-Chair of the Non-Hodgkin Lymphoma Disease Committee, 2010-2021) and participates in integrated translational research in pediatric lymphoma. Her research interests are focused on elucidating mechanisms involved in lymphoma pathogenesis which are supported by the NIH. She has participated and directed numerous CME activities for AMP, ASCP, CAP, and the USCAP.
Dr Mascarin
CRO Centro di Riferimento Oncologico
Medical Doctor (University degree, Trieste 1987), specialist in Pediatrics (Trieste 1991) and Radiotherapy-Oncology (Modena 1995). I attended Pediatric Hospital Burlo…
Medical Doctor (University degree, Trieste 1987), specialist in Pediatrics (Trieste 1991) and Radiotherapy-Oncology (Modena 1995). I attended Pediatric Hospital Burlo Garofolo Trieste (1987 -1991), Stanford University Hospital in Palo Alto (June 2004) and S.Jude Children Hospital in Memphis (Oct 2005). Since Dec 1991 employed full-time at “Radiotherapy Oncology Unit” of CRO Centro di Riferimento Oncologico IRCCS, Aviano (Italy). Since Jan 2007 director of the “AYA Oncology and Pediatric Radiotherapy Unit” in the same Institute. National Coordinator for Italy of the EuroNet-PHL-C2 trial. Author / co-author of 73 publications on international journals; 3 publications of international book chapters; several active participations as lecturer / speaker / moderator at scientific conferences. Area of interest: pediatric radiotherapy, tumors in AYA and adolescents, Hodgkin lymphoma, brain tumors, sarcomas, long-term sequelae of therapies, adolescence.
Prof. Mauz-Körholz
Justus-Liebig University
E DU C A T I O N AN D T R AI N I NG
1990 M.D. degree, University of Tübingen, Germany
1991 Dissertation, University of Düsseldorf, Germany…
E DU C A T I O N AN D T R AI N I NG
1990 M.D. degree, University of Tübingen, Germany
1991 Dissertation, University of Düsseldorf, Germany
1990-1999 Residency in Pediatrics and Research Fellow, Department of Pediatrics, Heinrich-Heine-University Düsseldorf
2000-2002 Research Fellow, Department of Pediatrics, University of Leipzig
2003 Habilitation, Assistant Professor of Pediatrics, University of Leipzig
W O R K EX P ER I EN C E / M A J OR P OS IT ION S
2003-2005 Medical monitor/study director and vice chairperson of the German Pediatric Hodgkin`s Study
Group (GPOH-HD)
2005 Scientific Secretary of the European Network of Pediatric Hodgkin`s Lymphoma Group (EuroNet-PHL-Group)
2006-2015 Head of the Centre for Clinical Trials Section at the Department of Pediatrics, Assistant Professor in
Pediatric Oncology, Hematology and Head of the Pediatric Stem Cell Transplantation Programme, Department of Pediatrics, Martin-Luther-University of Halle-Wittenberg
2011 Associate Professor of Pediatrics of the Martin-Luther-University of Halle-Wittenberg
Aug 2015-Oct 2015 Acting Director of the Department of Pediatrics, Martin-Luther-University of Halle-Witten-berg
Nov 2015 Head of the Reference Centre for Pediatric Hodgkin Lymphoma and Director of the Pediatric Stem
Cell Transplantation Programme, Department of Pediatric Hematology and Oncology, Justus-Liebig-University of Gießen
H O N O U R S AN D AW A R D S
2011 Arthur-Schlossmann-Preis
2014 Editorial Board Member „Journal of Clinical Oncology“
2015 Member of the Cancer Trials Committee, Stiftung Deutsche Krebshilfe
S HO R T HI G HL I G HT S O F R U N N I N G AN D F U T U R E P R O JE C TS
EuroNet-PHL-C2 trial: Deputy Chief Investigator and Head of the PHL Central Review Board
KEYNOTE-667 trial: Global Chief Investigator clinical trial, Co-PI liquid biopsy study
Checkmate-744 trial: Chief investigator in Germany
Design of a phase II allogeneic SCT trial for rel/ref HL patients
Congress-Co-Chair with Monika Metzger of the three-yearly ISCAYAHL (www.iscayahl.com)
Dr McCarten
Rhode Island Medical Imaging
In 1996 I joined the Pediatric Radiology department at Hasbro Children’s Hospital in Providence, Rhode Island, a Brown University affiliate. Since 2006 in my non-clinical…
In 1996 I joined the Pediatric Radiology department at Hasbro Children’s Hospital in Providence, Rhode Island, a Brown University affiliate. Since 2006 in my non-clinical hours I have been interpreting imaging for COG protocols involving Hodgkin Lymphoma in children, adolescents and young adults which I have done at QARC (Quality Assurance Review Center), later merged with IROCRI (Imaging and Radiation Oncology Core Group/Rhode Island) where data is stored for many multicenter trials related to oncology.
Because of the number of cases that I have reviewed for protocols and also consultations, I have obtained considerable experience in the imaging findings of Hodgkin lymphoma and its evolution with therapy. The development of newer imaging modalities also has allowed additional new insight into multiple aspects of the disease.
Dr Metzger
St. Jude Children´s Research Hospital
Dr. Monika Metzger is the Director for the South and Central American Region in the Department of Global Pediatric Medicine at St Jude Children’s Research…
Dr. Monika Metzger is the Director for the South and Central American Region in the Department of Global Pediatric Medicine at St Jude Children’s Research Hospital. Her main academic contributions have been in the field of Hodgkin lymphoma leading for 15 years a multi-institutional consortium for pediatric Hodgkin lymphoma protocols in the US and collaborating with Central America, Argentina, Brazil, Mexico and other Latinamerican countries on a common pediatric Hodgkin lymphoma protocol. Furthermore, as co-chair and founder of the International Symposium for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (ISCAYAHL) that first took place in Arlington Virginia in 2011 but takes place every 3 years alternating between the US and Germany she continuously mentors young investigators around the world and has been invited by different groups to consult on their treatment strategies.
Dr Mottok
University Hospital Gießen and Marburg GmbH
To follow
Prof. Parsons
Tufts Medical Center
Dr. Susan Parsons is a Professor of Medicine and Pediatrics at Tufts University School of Medicine, Director of the Center for Health Solutions within the Institute for…
Dr. Susan Parsons is a Professor of Medicine and Pediatrics at Tufts University School of Medicine, Director of the Center for Health Solutions within the Institute for Clinical Research and Health Policy Studies, and founding Medical Director of the Reid R. Sacco AYA Cancer Program at Tufts Medical Center. Her career has combined formal graduate training in health economics and planning, with extensive clinical training and experience in hematology/oncology, and cancer survivorship. Her research has focused on strategies to improve the patient’s experience with healthcare, reduce regimen-related toxicity, and optimize functioning. Nationally, she serves as a member of the Children’s Oncology Group’s (COG) Steering Committees for Hodgkin Lymphoma (HL), AYA Oncology, and Survivorship and Outcomes. She serves as the chair of cancer care delivery research (CCDR) for COG and has served as a member of the NCI’s Scientific Steering for CCDR for almost seven years. She is co-founder of the newly established HoLISTIC Consortium (Hodgkin Lymphoma International Study for Individual Care) with the goal of enhancing patient-provider communication on treatment trade-offs in HL.
Dr de Paula
Barretos Cancer Hospital
Master in Oncology acting as Pediatric Oncologist, Medical Director and Teaching Coordinator at Hospital Infanto-juvenil de Cancer, Fundação Pio XII de…
Master in Oncology acting as Pediatric Oncologist, Medical Director and Teaching Coordinator at Hospital Infanto-juvenil de Cancer, Fundação Pio XII de Barretos-SP- Brazil. Experience in Medicine, Medical Education and Active Methodologies, with an emphasis on Medicine, acting on the following topics: children, neoplasm, treatment, myelodysplastic syndromes, Hodgkin's Lymphoma, hematological diseases, educational health processes.
Dr Prestidge
Starship Childen´s Hospital
Tim Prestidge BHB MBChB FRACP FRCPA is a clinical hematologist-oncologist and a laboratory hematopathologist. After obtaining his medical degree…
Tim Prestidge BHB MBChB FRACP FRCPA is a clinical hematologist-oncologist and a laboratory hematopathologist. After obtaining his medical degree at the University of Auckland, his post graduate studies granted Fellowship into both the Australasian College of Physicians and the College of Pathologists in 2009. Prior to this current appointments he was at BC Children’s Hospital Vancouver Canada before moving to Starship Children’s Hospital in 2011. Currently he Chairs the Bone Marrow Transplant Advisory Committee for Auckland City Hospital and sits on several Australian and New Zealand advisory and clinical practise committees and subgroups in the field of lymphoid malignancies.
In regards to Hodgkin Lymphoma he initiated the cooperation and involvement of the Australia and New Zealand Children’s Oncology Group ANZCHOG into the EuroNet clinical trials for Hodgkin Lymphoma and developed the expansion of the Adolescent and Young Adult program to include these patients into the trials also from within Australasia.
Dr Savoldo
The University of North Carolina and Chapel Hill
My scientific training is in hematology and cancer immunology. I have studied the use of Epstein Barr Virus specific cytotoxic T-cells (CTLs) for therapy…
My scientific training is in hematology and cancer immunology. I have studied the use of Epstein Barr Virus specific cytotoxic T-cells (CTLs) for therapy of post-transplant virus-associated lymphoproliferative diseases and then extended my interest in cellular immunotherapy for non-viral associated malignancies. I am particularly interested in using T cells as platform for exploring genetic immune-manipulations to redirect them to target tumors by transgenic expression of alpha-betaTCRs or of chimeric tumor-specific receptors (CARs). My research also focuses on gene modification aimed at improving homing of T cells to tumor cells by expressing the appropriate chemokine receptor, improving their proliferation and persistence, and finally overcoming the inhibitory effect of the tumor environments. I have experience in translating preclinical studies with CAR T cells in clinical trials and contributed to the advance into the clinic of a safety switch for genetically modified T cells. Since joining the Lineberger Comprehensive Cancer Center (LCCC) at the University of North Carolina (UNC) at Chapel Hill, I am a professor in the Pediatric Department of Hematology-Oncology, and the co-director of the LCCC Immunotherapy Program. In addition to continue my interest in developing immunotherapy approaches for hematological and solid tumors, I facilitate the translation of preclinical approaches into successful clinical trials through collaborations with the UNC-LCCC GMP facility, the Regulatory Office, and Oncology Clinical Protocol Office. I have mentored numerous junior faculties, fellows, postdocs, and graduate students who have transitioned to become successful independent investigators in academia or industry.
Prof. Schmitz
Justus-Liebig Universität Gießen
Dr Schmitz is head of the department of molecular cytology and functional genomics and associate professor at the institute of pathology at the Justus Liebig University…
Dr Schmitz is head of the department of molecular cytology and functional genomics and associate professor at the institute of pathology at the Justus Liebig University Giessen, Germany. His research work focuses on multidisciplinary genetic and biochemical approaches to identify genetic alterations that contribute to the transformation of aggressive B-cell lymphomas. Dr Schmitz has discovered and functionally characterized several oncogenic lesions in Hodgkin and Non-Hodgkin Lymphomas. In 2018, he received the National Cancer Institute Director’s Award. Dr Schmitz serves as an associate editor for Leukemia (Springer Nature).
Dr Schwartz
Medical College of Wisconsin
Dr. Schwartz is the Chief of Pediatric Hematology, Oncology and Bone Marrow Transplantion, Professor Pediatrics (with tenure), and the Rebecca Slye Chair of Oncology at…
Dr. Schwartz is the Chief of Pediatric Hematology, Oncology and Bone Marrow Transplantion, Professor Pediatrics (with tenure), and the Rebecca Slye Chair of Oncology at the Medical College of Wisconsin (MCW) and the Children’s Hospital of WI. She is also Associate Director for Pediatrics and Survivorship at the MCW Cancer Canter. She was previously the Division Head and Chair of Pediatrics ad interim and the Deputy Chair for Clinical and Translational Research in Pediatrics at MD Anderson Cancer Center, Houston, the Chief of Pediatric Hematology Oncology at Brown University, and the Associate Director for Clinical Programs at Johns Hopkins. She is a graduate of Yale College, Brown University Program in Medicine, and the Harvard T.H. Chan School of Public Health. Her pediatric residency and pediatric hematology-oncology fellowship were at Johns Hopkins.
Dr. Schwartz was the inaugural Chair of the Children’s Oncology Group Hodgkin Lymphoma Committee (2001-11). Previously, she was Chair of the Pediatric Oncology Group HL Committee. Dr. Schwartz led the strategy to limit toxicity and improve efficacy by the use of response based therapies that tailor treatments to the individual patient. As Chair of POG 9425, she developed the dose-dense ABVE-PC regimen which has been the backbone therapy in COG Hodgkin Lymphoma trials for more than two decades. She also developed the pediatric CHIPS score, a predictor of clinical outcome in pediatric Hodgkin Lymphoma and was the clinical PI for the first SPORE project involving children (PI: R. Ambinder, EBV in Pediatric HL, Johns Hopkins Lymphoma Spore). Dr. Schwartz continues as a COG Hodgkin Lymphoma Steering Committee member and senior advisor.
In addition to her leadership in the area of Hodgkin Lymphoma, Dr. Schwartz’s expertise in pediatric oncology includes her current responsibilities as Chair of the COG Hematology Oncology Discipline Steering Committee, as Chair of the NANT (Novel Approaches to Neuroblastoma therapy) DSMB, as a COG Bone Tumor Steering Committee membership and as a member of the St. Jude Children’s Research Hospital DSMB. Dr. Schwartz has a long-standing expertise in the late effects of childhood cancer, having established survivorship programs at the University of Rochester, Brown, and Johns Hopkins. She looks forward to the day when all patients with Hodgkin Lymphoma can look forward to long and healthy lives.
Dr Steidl
BC Cancer
Dr Steidl is the Research Director of the Centre for Lymphoid Cancer, Associate Vice President Research at BC Cancer and Professor in the Department of…
Dr Steidl is the Research Director of the Centre for Lymphoid Cancer, Associate Vice President Research at BC Cancer and Professor in the Department of Pathology and Laboratory Medicine at the University of British Columbia. Dr. Steidl’s translational research group focuses on the pathogenesis of B cell lymphomas, tumor microenvironment biology and applied genomics. He is most known for his discovery and characterization of novel gene mutations and microenvironment-related biomarkers in Hodgkin and Non-Hodgkin lymphomas. Dr Steidl is a member of the Scientific Advisory Board of the Lymphoma Research Foundation, past Chair of the American Society of Hematology Scientific Committee on Lymphoid Neoplasia and Member of the Leukemia and Lymphoma Society of Canada Medical and Scientific Advisory Committee. He was inducted as a member of the Royal Society of Canada, College for New Scholars, Artists and Scientists in 2017, and won an Allen Distinguished Investigator award in 2018.
Dr Stoevesandt
Martin Luther Universität Halle Wittenberg
To follow
Dr Super
Monash Children´s Hospital
Paediatric Oncologist in Melbourne, Australia.
Special interest in AYA, Hodgkin lymphoma, LCH, other solid tumours, leukaemia and lymphoma. Also involved…
Paediatric Oncologist in Melbourne, Australia.
Special interest in AYA, Hodgkin lymphoma, LCH, other solid tumours, leukaemia and lymphoma. Also involved in supportive care including onco-fertility, Low risk febrile neutropaenia.
Member of RACP, AMA, SIOP, ANZCHOG, ANZSA, HS, COG, Euronet, GLOW group, and involved with COG AYA RI working group.
National PI for Euronet HL C2 study, and co-PI for many national and international studies.
Studied medicine at Monash University, completed my Paediatrics and Paediatric Haematology/ Oncology training at RCH, Monash, UCLH, London and GOSH, London.
Many publications, presentations, posters over the years and attendance at national and international conferences.
Dr Tiacci
Istituto di Ematologia
After graduation in Medicine and residency in Hematology at the University of Perugia (Italy) under the supervision of Prof. M. F. Martelli and Prof. B. Falini, Enrico Tiacci…
After graduation in Medicine and residency in Hematology at the University of Perugia (Italy) under the supervision of Prof. M. F. Martelli and Prof. B. Falini, Enrico Tiacci trained in the molecular pathogenesis of lymphomas at the University of Essen (Germany) in the laboratory of Prof. R. Küppers.
He then established and independent translational and clinical research program in leukemias and lymphomas at the University and Hospital of Perugia, where he is Associate Professor of Hematology.
His most relevant recent scientific contributions to pathogenesis, diagnosis and therapy of blood cancers include the following:
- The discovery of BRAF mutation as the genetic cause of hairy cell leukemia, its diagnostic exploitation and its therapeutic targeting in the clinic.
- The discovery of disruptive BCOR mutations in acute myeloid leukemias
- The study of high-risk clonal hematopoiesis in patients with myeloid and lymphoid neoplasms
- The transcriptional characterization of classical Hodgkin lymphoma (cHL) and of its potential normal cell counterpart (CD30+B cells), followed by the definition of the cHL coding genome and the identification of new frequently mutated genes in this neoplasm (e.g., STAT6 and GNA13).
He published as author and acted as reviewer in journals like the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Lancet Oncology, Journal of Clinical Investigations and Blood Cancer Discovery.
He received national and international recognitions for his achievements, including:
- International "Future Leaders in Hematology Award" from Celgene (selection by an independent scientific committee; San Diego - CA, USA - 2011)
- Scholarship in Clinical Research awarded from the Leukemia and Lymphoma Society (USA - 2013)
- Consolidator Grant from the European Research Council (2014)
- International "Young Investigator Award" for Clinical Research in Hematology from Celgene (selection by an independent scientific committee; Orlando - FL, USA - 2015)
- International "Francesco De Luca" Award for Cancer Research from the National Lyncean Academy (Accademia Nazionale dei Lincei; Rome, Italy - 2017)
Dr Veron
Hospital Universitario Austral
Graduated with an Honor Diploma from the Faculty of Medicine of the University of Buenos Aires (UBA) in 2002.
Residency in Pediatrics in 2007…
Graduated with an Honor Diploma from the Faculty of Medicine of the University of Buenos Aires (UBA) in 2002.
Residency in Pediatrics in 2007.
Fellow in Pediatric Hematology and Oncology in 2010.
Career of Medical Specialist in Hematology, Argentine Society of Hematology (SAH) - University of Buenos Aires, 2009.
Postgraduate Training in Haemostasis and Thrombosis, Institute of Hematological Research "Mariano Castex", National Academy of Medicine, Buenos Aires, Argentina (2009).
Postgraduate Training in Immunotherapy and Leukemia at the Sant Joan de Déu Hospital, Barcelona, Spain (2019).
First Assistant of Internal Medicine of the Medicine career, University of Buenos Aires.
Professor of the Career of Medical Specialist in Hematology: UBA - SAH.
Principal Coordinator of the Pediatric Hodgkin Lymphoma Commission of the GATLA Group since 2012.
CLEHOP member.
Senior Staff in the Pediatric Hematologý and Oncology Service of the Hospital Universitario Austral, Pilar, Argentina.
Full Member and Current Member of the Board of Directors of the Argentine Society of Hematology.
Full Member of the CAHT Group (Argentine Cooperative Group for Haemostasis and Thrombosis).
Member of the AMERICAN SOCIETY OF HEMATOLOGY (ASH) since 2016.
Prof. Wallace
University of Edinburgh, Royal Hospital for Sick Children
Current Position:
Consultant Paediatric Oncologist, RHSC, Edinburgh since 1992…
Current Position:
Consultant Paediatric Oncologist, RHSC, Edinburgh since 1992
Honorary Professor in the School of Clinical Sciences and Community Heath at the University of Edinburgh.
Qualified:
St George’s Hospital Medical School in 1980.
I trained in paediatric oncology at Great Ormond Street Hospital, Birmingham, Manchester and Edinburgh.
Registered Qualifications: MD., FRCP., FRCPCH., FRCS
Summary: I am a Consultant in Paediatric Oncology at the Royal Hospital for Sick Children in Edinburgh and Honorary Professor at the University of Edinburgh.
My main research interests are in fertility prediction and preservation for young cancer patients, Hodgkin lymphoma and mathematical modelling of biological systems.
I am a co-author of more than 200 peer-reviewed publications (h index 78, i10 index 184), and four books. I am the co-founder and organiser for ESLCCC, a biannual International conference on the late effects of the treatment of childhood cancer.
My website for more information on our research developments is:
